Research on government subsidy strategies for new drug R&D considering spillover effects
This paper studies the pharmaceutical production supply chain system composed of upstream and downstream pharmaceutical enterprises, and explores the impact of government subsidy strategies on the new drug research and development (R&D) decision variables and profits of pharmaceutical enterprise...
Gespeichert in:
| Veröffentlicht in: | PloS one 2022-02, Vol.17 (2), p.e0262655-e0262655 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0262655 |
|---|---|
| container_issue | 2 |
| container_start_page | e0262655 |
| container_title | PloS one |
| container_volume | 17 |
| creator | Huang, Zhe Lan, Yipeng Zha, Xiangqi |
| description | This paper studies the pharmaceutical production supply chain system composed of upstream and downstream pharmaceutical enterprises, and explores the impact of government subsidy strategies on the new drug research and development (R&D) decision variables and profits of pharmaceutical enterprises as well as social welfare, when considering both the horizontal spillover effects within the industry and the vertical spillover effects between industries. Comparing and analyzing the impact of these strategies including non-government subsidy strategy, pharmaceutical enterprise innovation input subsidy strategy, pharmaceutical enterprise innovative product subsidy strategy, patient price subsidy strategy, and patient medical insurance subsidy strategy. By establishing a four-stage Cournot duopoly model incorporating spillover effects, the equilibrium solutions are obtained by backward induction, and the impact of spillover effects on decision variables is investigated accordingly. Studies have shown that: (a) Government subsidy strategies can promote pharmaceutical enterprises' R&D investment and have a positive incentive effect on the pharmaceutical enterprises' profits and social welfare. (b) The patient medical insurance subsidy strategy is the optimal subsidy strategy, which can generate higher profits for pharmaceutical enterprises and higher social welfare. |
| doi_str_mv | 10.1371/journal.pone.0262655 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2627455007</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A692894604</galeid><sourcerecordid>A692894604</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5415-16be2e2bec3f26b231b20b70191bad7ffb3faa8631e7087fa3c1ac72a55fcf223</originalsourceid><addsrcrecordid>eNqNkl1rFDEUhgdRbK3-A9GAUPRi13xMMjM3QqlfhUJh_cC7kMmczKZkk20yo_bfm7XTsiO9kFwkJM97TvLmLYrnBC8Jq8jbyzBGr9xyGzwsMRVUcP6gOCQNowtBMXu4tz4onqR0iTFntRCPiwPGScnKRhwWP1aQQEW9RsGjPvyE6DfgB5TGNtnuGqUhqgF6CwmZEJGHX6iLY49Wx--RDj4zEK3vUdpa53ZyBMaAHtLT4pFRLsGzaT4qvn388PX08-L84tPZ6cn5QvOS8AURLVCgLWhmqGgpIy3FbYVJQ1rVVca0zChVC0agwnVlFNNE6Yoqzo02lLKj4uVN3a0LSU6mJJn9qErOMa4y8W4ixnYDnc7Pi8rJbbQbFa9lUFbOT7xdy2yFrGuGRcVygddTgRiuRkiD3NikwTnlIYx_e9W0EaJpMvrqH_T-G01UrxxI603IffWuqDwRDa2bUuAyU8t7qDw62NjsPRib92eCNzNBZgb4PfRqTEmefVn9P3vxfc4e77FrUG5Yp-DGweYAzMHyBtQxpBTB3JlMsNyF9tYNuQutnEKbZS_2P-hOdJtS9gdf0Og9</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627455007</pqid></control><display><type>article</type><title>Research on government subsidy strategies for new drug R&D considering spillover effects</title><source>Public Library of Science (PLoS) Journals Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Huang, Zhe ; Lan, Yipeng ; Zha, Xiangqi</creator><creatorcontrib>Huang, Zhe ; Lan, Yipeng ; Zha, Xiangqi</creatorcontrib><description>This paper studies the pharmaceutical production supply chain system composed of upstream and downstream pharmaceutical enterprises, and explores the impact of government subsidy strategies on the new drug research and development (R&D) decision variables and profits of pharmaceutical enterprises as well as social welfare, when considering both the horizontal spillover effects within the industry and the vertical spillover effects between industries. Comparing and analyzing the impact of these strategies including non-government subsidy strategy, pharmaceutical enterprise innovation input subsidy strategy, pharmaceutical enterprise innovative product subsidy strategy, patient price subsidy strategy, and patient medical insurance subsidy strategy. By establishing a four-stage Cournot duopoly model incorporating spillover effects, the equilibrium solutions are obtained by backward induction, and the impact of spillover effects on decision variables is investigated accordingly. Studies have shown that: (a) Government subsidy strategies can promote pharmaceutical enterprises' R&D investment and have a positive incentive effect on the pharmaceutical enterprises' profits and social welfare. (b) The patient medical insurance subsidy strategy is the optimal subsidy strategy, which can generate higher profits for pharmaceutical enterprises and higher social welfare.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0262655</identifier><identifier>PMID: 35143496</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Biology and Life Sciences ; Decision making ; Drug discovery ; Drug Industry - economics ; Economic aspects ; Equilibrium ; Evaluation ; Financing, Government ; Government subsidies ; Health insurance ; Health risks ; Impact analysis ; Innovations ; Insurance ; Literature reviews ; Medical innovations ; Medicine and Health Sciences ; Models, Theoretical ; Patients ; Pharmaceutical industry ; Pharmaceutical laws ; Pharmaceutical Preparations - supply & distribution ; Pharmaceuticals ; Profits ; R&D ; Research & development ; Research - economics ; Social factors ; Social Sciences ; Social Welfare ; Subsidies ; Supply chains</subject><ispartof>PloS one, 2022-02, Vol.17 (2), p.e0262655-e0262655</ispartof><rights>(c) The horizontal and vertical spillover effects have different effect on decision variables, enterprises' profits and social welfare under various subsidy strategies.</rights><rights>COPYRIGHT 2022 Public Library of Science</rights><rights>2022 Huang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 Huang et al 2022 Huang et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5415-16be2e2bec3f26b231b20b70191bad7ffb3faa8631e7087fa3c1ac72a55fcf223</citedby><cites>FETCH-LOGICAL-c5415-16be2e2bec3f26b231b20b70191bad7ffb3faa8631e7087fa3c1ac72a55fcf223</cites><orcidid>0000-0002-3170-9341</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830673/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830673/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2915,23845,27901,27902,53766,53768,79569,79570</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35143496$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Zhe</creatorcontrib><creatorcontrib>Lan, Yipeng</creatorcontrib><creatorcontrib>Zha, Xiangqi</creatorcontrib><title>Research on government subsidy strategies for new drug R&D considering spillover effects</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>This paper studies the pharmaceutical production supply chain system composed of upstream and downstream pharmaceutical enterprises, and explores the impact of government subsidy strategies on the new drug research and development (R&D) decision variables and profits of pharmaceutical enterprises as well as social welfare, when considering both the horizontal spillover effects within the industry and the vertical spillover effects between industries. Comparing and analyzing the impact of these strategies including non-government subsidy strategy, pharmaceutical enterprise innovation input subsidy strategy, pharmaceutical enterprise innovative product subsidy strategy, patient price subsidy strategy, and patient medical insurance subsidy strategy. By establishing a four-stage Cournot duopoly model incorporating spillover effects, the equilibrium solutions are obtained by backward induction, and the impact of spillover effects on decision variables is investigated accordingly. Studies have shown that: (a) Government subsidy strategies can promote pharmaceutical enterprises' R&D investment and have a positive incentive effect on the pharmaceutical enterprises' profits and social welfare. (b) The patient medical insurance subsidy strategy is the optimal subsidy strategy, which can generate higher profits for pharmaceutical enterprises and higher social welfare.</description><subject>Biology and Life Sciences</subject><subject>Decision making</subject><subject>Drug discovery</subject><subject>Drug Industry - economics</subject><subject>Economic aspects</subject><subject>Equilibrium</subject><subject>Evaluation</subject><subject>Financing, Government</subject><subject>Government subsidies</subject><subject>Health insurance</subject><subject>Health risks</subject><subject>Impact analysis</subject><subject>Innovations</subject><subject>Insurance</subject><subject>Literature reviews</subject><subject>Medical innovations</subject><subject>Medicine and Health Sciences</subject><subject>Models, Theoretical</subject><subject>Patients</subject><subject>Pharmaceutical industry</subject><subject>Pharmaceutical laws</subject><subject>Pharmaceutical Preparations - supply & distribution</subject><subject>Pharmaceuticals</subject><subject>Profits</subject><subject>R&D</subject><subject>Research & development</subject><subject>Research - economics</subject><subject>Social factors</subject><subject>Social Sciences</subject><subject>Social Welfare</subject><subject>Subsidies</subject><subject>Supply chains</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkl1rFDEUhgdRbK3-A9GAUPRi13xMMjM3QqlfhUJh_cC7kMmczKZkk20yo_bfm7XTsiO9kFwkJM97TvLmLYrnBC8Jq8jbyzBGr9xyGzwsMRVUcP6gOCQNowtBMXu4tz4onqR0iTFntRCPiwPGScnKRhwWP1aQQEW9RsGjPvyE6DfgB5TGNtnuGqUhqgF6CwmZEJGHX6iLY49Wx--RDj4zEK3vUdpa53ZyBMaAHtLT4pFRLsGzaT4qvn388PX08-L84tPZ6cn5QvOS8AURLVCgLWhmqGgpIy3FbYVJQ1rVVca0zChVC0agwnVlFNNE6Yoqzo02lLKj4uVN3a0LSU6mJJn9qErOMa4y8W4ixnYDnc7Pi8rJbbQbFa9lUFbOT7xdy2yFrGuGRcVygddTgRiuRkiD3NikwTnlIYx_e9W0EaJpMvrqH_T-G01UrxxI603IffWuqDwRDa2bUuAyU8t7qDw62NjsPRib92eCNzNBZgb4PfRqTEmefVn9P3vxfc4e77FrUG5Yp-DGweYAzMHyBtQxpBTB3JlMsNyF9tYNuQutnEKbZS_2P-hOdJtS9gdf0Og9</recordid><startdate>20220210</startdate><enddate>20220210</enddate><creator>Huang, Zhe</creator><creator>Lan, Yipeng</creator><creator>Zha, Xiangqi</creator><general>Public Library of Science</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3170-9341</orcidid></search><sort><creationdate>20220210</creationdate><title>Research on government subsidy strategies for new drug R&D considering spillover effects</title><author>Huang, Zhe ; Lan, Yipeng ; Zha, Xiangqi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5415-16be2e2bec3f26b231b20b70191bad7ffb3faa8631e7087fa3c1ac72a55fcf223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biology and Life Sciences</topic><topic>Decision making</topic><topic>Drug discovery</topic><topic>Drug Industry - economics</topic><topic>Economic aspects</topic><topic>Equilibrium</topic><topic>Evaluation</topic><topic>Financing, Government</topic><topic>Government subsidies</topic><topic>Health insurance</topic><topic>Health risks</topic><topic>Impact analysis</topic><topic>Innovations</topic><topic>Insurance</topic><topic>Literature reviews</topic><topic>Medical innovations</topic><topic>Medicine and Health Sciences</topic><topic>Models, Theoretical</topic><topic>Patients</topic><topic>Pharmaceutical industry</topic><topic>Pharmaceutical laws</topic><topic>Pharmaceutical Preparations - supply & distribution</topic><topic>Pharmaceuticals</topic><topic>Profits</topic><topic>R&D</topic><topic>Research & development</topic><topic>Research - economics</topic><topic>Social factors</topic><topic>Social Sciences</topic><topic>Social Welfare</topic><topic>Subsidies</topic><topic>Supply chains</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Zhe</creatorcontrib><creatorcontrib>Lan, Yipeng</creatorcontrib><creatorcontrib>Zha, Xiangqi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection (ProQuest)</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Zhe</au><au>Lan, Yipeng</au><au>Zha, Xiangqi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Research on government subsidy strategies for new drug R&D considering spillover effects</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2022-02-10</date><risdate>2022</risdate><volume>17</volume><issue>2</issue><spage>e0262655</spage><epage>e0262655</epage><pages>e0262655-e0262655</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>This paper studies the pharmaceutical production supply chain system composed of upstream and downstream pharmaceutical enterprises, and explores the impact of government subsidy strategies on the new drug research and development (R&D) decision variables and profits of pharmaceutical enterprises as well as social welfare, when considering both the horizontal spillover effects within the industry and the vertical spillover effects between industries. Comparing and analyzing the impact of these strategies including non-government subsidy strategy, pharmaceutical enterprise innovation input subsidy strategy, pharmaceutical enterprise innovative product subsidy strategy, patient price subsidy strategy, and patient medical insurance subsidy strategy. By establishing a four-stage Cournot duopoly model incorporating spillover effects, the equilibrium solutions are obtained by backward induction, and the impact of spillover effects on decision variables is investigated accordingly. Studies have shown that: (a) Government subsidy strategies can promote pharmaceutical enterprises' R&D investment and have a positive incentive effect on the pharmaceutical enterprises' profits and social welfare. (b) The patient medical insurance subsidy strategy is the optimal subsidy strategy, which can generate higher profits for pharmaceutical enterprises and higher social welfare.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>35143496</pmid><doi>10.1371/journal.pone.0262655</doi><tpages>e0262655</tpages><orcidid>https://orcid.org/0000-0002-3170-9341</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2022-02, Vol.17 (2), p.e0262655-e0262655 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2627455007 |
| source | Public Library of Science (PLoS) Journals Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Biology and Life Sciences Decision making Drug discovery Drug Industry - economics Economic aspects Equilibrium Evaluation Financing, Government Government subsidies Health insurance Health risks Impact analysis Innovations Insurance Literature reviews Medical innovations Medicine and Health Sciences Models, Theoretical Patients Pharmaceutical industry Pharmaceutical laws Pharmaceutical Preparations - supply & distribution Pharmaceuticals Profits R&D Research & development Research - economics Social factors Social Sciences Social Welfare Subsidies Supply chains |
| title | Research on government subsidy strategies for new drug R&D considering spillover effects |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T09%3A24%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Research%20on%20government%20subsidy%20strategies%20for%20new%20drug%20R&D%20considering%20spillover%20effects&rft.jtitle=PloS%20one&rft.au=Huang,%20Zhe&rft.date=2022-02-10&rft.volume=17&rft.issue=2&rft.spage=e0262655&rft.epage=e0262655&rft.pages=e0262655-e0262655&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0262655&rft_dat=%3Cgale_plos_%3EA692894604%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2627455007&rft_id=info:pmid/35143496&rft_galeid=A692894604&rfr_iscdi=true |